media – Page 56 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Kunyao Group’s Class 1 new drug is coming! Seize the market worth 210 billion yuan

Recently, the CDE official website showed that KPC000154 tablets, a Class 1 new drug declared by Kunming Pharmaceutical Group, have obtained implied approval for clinical trials, with indications for non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive system and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets (detailed statistical scope at the end of this article) will exceed 210 billion yuan in 2023. Reference No. Drug name Applicant name Indication Registration classification CXHL2400923 KPC000154 pills KPC (Hengqin, Zhuhai) Technology Co., Ltd; KPC Pharmaceuticals Inc. NASH 1 CXGL2400922 KPC000154 pills KPC (Hengqin, Zhuhai) Technology Co., Ltd; KPC Pharmaceuticals Inc. NASH 1 KPC000154 tablets are a Class 1 innovative drug independently developed by Kunming Pharmaceutical Group. Its clinical application was accepted by CDE in September 2024 and was recently approved for clinical use in the treatment of non-alcoholic fatty liver disease. According ...
- Source: drugdu
- 102
- November 26, 2024
Siemens Healthineers and Densburg Sinode collaborate to install the world’s first dental-dedicated MRI

Recently, Denspensinord and Siemens Healthineers announced a partnership with the School of Dentistry at the University of Minnesota to install the first dental dedicated MRI (ddMRI) in the United States. It is reported that the research project will explore the planned MAGNETOM Free The potential features of Max Dental Edition for dental imaging and diagnosis include the potential advantages of ddMRI in preventing and correcting oral care. Based on the proven outstanding achievements of the University of Minnesota Magnetic Resonance Research Center in MRI research, Denspensinord and Siemens Healthineers have decided to install the system at the school’s School of Dentistry for research purposes. 01. Installation of the first dental specific MRI According to the data, the MAGNETOM Free. Max Dental Edition MRI system is a joint research initiative between Densburg Sinode and Siemens Healthineers aimed at exploring new opportunities in the field of dental imaging. By utilizing MRI to ...
- Source: drugdu
- 84
- November 26, 2024
KPC Pharmaceuticals Inc.’s Class 1 new drug is about to seize the market

Recently, the CDE official website showed that KPC000154 tablets, a Class 1 new drug declared by Kunming Pharmaceutical Group, have obtained implied approval for clinical trials, with indications for non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive system and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets (detailed statistical scope at the end of this article) will exceed 210 billion yuan in 2023. KPC000154 tablets are a Class 1 innovative drug independently developed by Kunming Pharmaceutical Group. Its clinical application was accepted by CDE in September 2024 and was recently approved for clinical use in the treatment of non-alcoholic fatty liver disease. According to data from MineNet, the sales of digestive systems and metabolic drugs (chemical+biological) in China’s three major terminal markets and six major markets will remain above 210 billion yuan from 2021 to 2023, but will continue to ...
- Source: drugdu
- 133
- November 26, 2024
Haobo Medical ASO treats hepatitis B, with a negative conversion rate of over 60%

Hepatitis B, as one of the common infectious diseases worldwide, has long troubled the medical community and patients. Although a variety of treatments are available, achieving functional cure of hepatitis B has always been the focus and difficulty of medical research. Recently, according to a report by “Liver Time”, Haobo Pharmaceutical has made breakthrough progress in the treatment of hepatitis B through its independently developed ASO therapy AHB-137. Clinical trial data shows that the HBsAg negative conversion rate of AHB-137 exceeds 60%. It provides new hope for the treatment of hepatitis B. AHB-137 is carefully developed by Haobo Pharmaceutical through its unique scientific research platform Med-Oligo™. This ASO (antisense oligonucleotide) drug has shown remarkable results in clinical trials for the treatment of hepatitis B. According to public data, among patients with baseline HBsAg levels of 100-3000IU/ml, after 12 weeks of treatment, 62% and 43% of patients in the 300 mg ...
- Source: drugdu
- 182
- November 26, 2024
Overly worried about the “scissors gap” of medical insurance revenue and expenditure

Regarding the problem of the “scissors gap” of medical insurance, we need to worry, but we also need to have confidence in solving it. Although the long-term pressure on medical insurance funds is increasing under the severe situation of population aging, ten years ago, there were still three employees supporting one retired employee. Last year, the ratio of employees’ basic medical insurance to retired employees dropped to 2.71. In the long run, there may be fewer and fewer people paying money, and more and more people spending money, and the medical expenses of the elderly will increase with age. This “scissors gap” will undoubtedly bring huge pressure to the sustainability of medical insurance financing and operation. However, there are always more solutions than difficulties. Referring to Japan, where the aging population is more serious, in addition to drastic price control reforms, Japan has promoted the operation of the national health ...
- Source: drugdu
- 68
- November 26, 2024
BeiGene’s Category 1 innovative cancer drug has been approved for clinical trials! New target for “synthetic lethality”

On November 19, the official website of the Center for Drug Evaluation (CDE) of the China State Food and Drug Administration announced that BGB-58067, a Class 1 new drug submitted by BeiGene, has received implicit approval for clinical trials and is planned to be developed to treat patients with advanced solid tumors. According to BeiGene’s public information, BGB-58067 is a PRMT5 inhibitor and one of BeiGene’s future core projects. According to the CDE official website, this is the first time this product has been approved for clinical use in China. PRMT5 is a new target in the field of “synthetic lethality”. Research has found that the gene that constitutes “synthetic lethality” with PRMT5 is MTAP, which is a tumor suppressor gene that is often deleted in tumors. Loss of MTAP will cause the accumulation of its reaction substrate methylthioadenosine (MTA), and MTA will combine with PRMT5 to form a PRMT5-MTA ...
- Source: drugdu
- 121
- November 26, 2024
Nearly 97% of patients reached lipoprotein standards within 3 months! Eli Lilly announces impressive results for oral inhibitor

Eli Lilly and Company recently announced that its investigational once-daily oral lipoprotein(a)-Lp(a) inhibitor muvalaplin achieved positive results in a Phase 2 clinical trial. The study showed that the trial met the primary endpoint. Muvalaplin could significantly reduce elevated Lp(a) levels in adult patients, and the patients’ percentage change in Lp(a) levels from baseline to week 12 showed significant improvement. These data were published in the journal JAMA and released simultaneously at the 2024 American Heart Association (AHA) Annual Scientific Meeting. Muvalaplin is an orally administered small molecule that inhibits Lp(a) formation by blocking the apo(a)-apo B100 interaction while avoiding the interaction with the homologous protein plasminogen. The analysis showed that muvalaplin (10 mg, 60 mg and 240 mg) significantly reduced patients’ Lp(a) levels in the primary endpoint at week 12. Placebo-adjusted Lp(a) reductions were up to 85.8% as assessed by the intact Lp(a) assay and up to 70.0% as assessed ...
- Source: drugdu
- 137
- November 26, 2024
KIMES

Organiser：Korea E & Ex Inc., Korea Medical Device Industry Association Time：March 20th – 23rd, 2025 Address：513, Yeongdong-daero, Gangnam-gu, Seoul Exhibition hall：COEX Convention & Exhibition Center Product range: Medical Equipment: Medical technology equipment, consumables, medical electronic equipment, ophthalmic equipment and protective products, surgical instruments, emergency response equipment, hospital, dental, and medical facilities, dental service equipment, disposable medical products for hospitals and households, hospital and dental medical data processing systems, dental plastic surgery, rehabilitation equipment, etc. In Vitro Diagnostics & Clinical Laboratory Equipment: Endoscopy systems, B-mode ultrasound, examination equipment, ENT treatment instruments, dynamic analysis instruments, comprehensive laboratory solutions, clinical diagnostic equipment, diagnostic reagents, precision medicine, POCT (Point of Care Testing) home diagnostic devices, clinical laboratory equipment. Rehabilitation & Nursing Products: Orthopedic devices, walkers, hearing aids, auditory warning devices for the blind, manual wheelchairs, electric wheelchairs, crutches, walking aids, massagers, health clothing, fitness equipment, training machines, wrist and ankle braces, wearable neck ...
- Source: drugdu
- 118
- November 26, 2024
16.5 billion big drug, the first domestic drug is about to be approved

Currently, there is only one Bcl-2 inhibitor in the world, venetoclax, which is jointly developed by AbbVie and Roche. AbbVie’s financial report shows that in 2023, venetoclax’s revenue will reach US$2.28 billion (approximately RMB 16.5 billion), a year-on-year increase of 13.9%. Such an attractive golden big single product, the first domestic drug is about to usher in a breakthrough. Recently, Ascent Pharmaceuticals announced that its independently developed new selective Bcl-2 inhibitor APG-2575’s new drug application (NDA) has been accepted by the CDE and recommended for inclusion in the priority review process for the treatment of refractory or relapsed (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first domestic original Bcl-2 inhibitor to submit an NDA in China, and is expected to become the second Bcl-2 inhibitor to be listed in the world. 16.5 billion big drug, the first domestic product is accelerating to the finish line. The “strongest ...
- Source: drugdu
- 86
- November 25, 2024
Domestic molecules become king bombs overseas

Recently, BionTech chose to go a step further after completing the BD transaction of Promis bispecific antibody: it completely acquired Promis, a Chinese multi-antibody biotech. The day after the announcement of the acquisition, BioNTech held the 2024 R&D Day in full swing. Most of the report was devoted to describing the cancer treatment strategy centered on the bispecific antibody PM8002 developed by Promis, and clarified that the acquisition of PM8002 is a highlight in the company’s future strategic blueprint. From 2023, we can see that BioNTech is frequently sweeping up domestic pipelines. A total of four ADC pipelines from two high-quality biotechs, Yilian and Yingen, as well as PM8002 from Promis, were all acquired by BioNTech. From the timeline, BioNTech first conducted BD transactions for several ADC pipelines in 2023, and then completed the BD of Promis bispecific antibody at the end of 2023. From today’s perspective, BioNTech regards PM8002 ...
- Source: drugdu
- 116
- November 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.